Instant Digital Pathology Market Global Report 2026

The instant digital pathology market size has grown rapidly in recent years. It will grow from $1.22 billion in 2025 to $1.44 billion in 2026 at a compound annual growth rate (CAGR) of 18.4%. The growth in the historic period can be attributed to increasing demand for faster cancer diagnosis, rising adoption of digital healthcare infrastructure, growing need for improved pathology workflow efficiency, increasing prevalence of chronic and oncology-related diseases, rising requirement for remote diagnostic capabilities.

The instant digital pathology market size is expected to see rapid growth in the next few years. It will grow to $2.85 billion in 2030 at a compound annual growth rate (CAGR) of 18.6%. The growth in the forecast period can be attributed to increasing adoption of precision medicine approaches, growing demand for decentralized pathology services, rising need for enhanced diagnostic accuracy, increasing healthcare investment in advanced laboratory solutions, expanding use of virtual pathology consultation models. Major trends in the forecast period include increasing adoption of ultra-fast whole slide imaging systems for real-time pathology assessment, growing integration of remote pathology platforms for instant expert consultation and diagnosis, rising demand for automated tissue analysis workflows to reduce diagnostic turnaround time, increasing deployment of high-resolution digital microscopy solutions in pathology laboratories, growing preference for seamless interoperability between digital pathology systems and laboratory information systems.

The increasing adoption of digital pathology in clinical diagnostics is expected to drive the growth of the instant digital pathology market going forward. Digital pathology refers to the conversion of conventional glass microscope slides into high-resolution digital images through the use of whole-slide scanning technology. The adoption of digital pathology in clinical diagnostics is increasing due to the growing need for faster, more precise, and AI-enabled diagnostic workflows that enhance laboratory efficiency and reduce reporting turnaround times. Instant digital pathology supports rapid slide digitization, real-time image accessibility, AI-based analysis, and quicker clinical decision-making while reducing delays associated with traditional pathology processes. For instance, in January 2025, according to Labcorp, a US-based clinical laboratory and diagnostics company, approximately one-third (33%) of clinical laboratories had adopted whole-slide imaging, demonstrating the continued expansion of digital pathology adoption despite cost-related barriers. Therefore, the increasing adoption of digital pathology in clinical diagnostics is driving the growth of the instant digital pathology market.

Key companies operating in the instant digital pathology market are concentrating on developing high-throughput whole-slide scanners and advanced digital pathology platforms to enable rapid, high-resolution digitization of pathology slides. High-throughput whole-slide scanners quickly transform pathology slides into high-resolution digital images, enabling faster diagnosis and AI-assisted workflows. For example, in January 2025, Roche Diagnostics, a Switzerland-based diagnostics division of Roche Holding AG, received U.S. FDA 510(k) clearance for its VENTANA DP 600 high-volume slide scanner as part of the Roche Digital Pathology Dx system. The scanner enables instant high-resolution slide digitization, rapid whole-slide image acquisition, and accelerated digital pathology workflows, allowing pathologists to perform faster primary diagnoses and clinical decision-making. It is designed for high-throughput pathology laboratories, supporting continuous slide scanning with consistent image quality across large sample volumes. It integrates seamlessly with Roche's digital pathology software ecosystem, enabling efficient image management, case review, and collaboration among pathologists. By reducing manual slide handling and supporting AI-enabled image analysis applications, the system helps enhance laboratory productivity, diagnostic accuracy, and turnaround times.

In August 2025, Tempus AI, a US-based precision medicine and artificial intelligence company, acquired Paige for $81.25 million. Through this acquisition, Tempus AI sought to enhance its digital pathology and artificial intelligence capabilities by expanding its collection of clinically annotated pathology datasets, accelerating the creation of AI-driven diagnostic solutions, and advancing precision oncology applications to support improved clinical decisions. Paige is a US-based company specializing in AI-enabled digital pathology solutions that assist with cancer diagnosis, biomarker identification, and optimization of pathology workflows.

Major companies operating in the instant digital pathology market report are F. Hoffmann-La Roche Ltd., Leica Biosystems, Hamamatsu Photonics K.K., Koninklijke Philips N.V., Sectra AB, Epredia, Proscia Inc., Indica Labs Inc., Paige AI Inc., OptraSCAN Inc., Motic Digital Pathology, Ibex Medical Analytics Ltd., 3DHISTECH Ltd., Huron Digital Pathology Inc., Aiforia Technologies Plc, Lunit Inc., Inspirata Inc., Grundium Oy, PathPresenter Inc., Corista LLC, Morphle Labs Inc.

North America was the dominant region in the instant digital pathology market in 2025. Asia-Pacific is expected to be the rapidly growing region in the forecast period. The regions covered in the instant digital pathology market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the instant digital pathology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

This product will be delivered within 3-5 business days.